Vascular endothelial growth factor expression and microvessel density - Two useful tools for the assessment of prognosis and survival in gastric cancer patients

Journal of Gastrointestinal and Liver Diseases

Volumn 19, Issue 2, 2010, Pages 135-139

  Iordache, Sevastita ^a   Saftoiu, Adrian ^a   Georgescu, Claudia Valentina ^a   Ramboiu, Sandu ^a   Gheonea, Dan Ionut ^a   Filip, Monalisa ^a   Schenker, Michael ^a   Ciurea, Tudorel ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Gastric cancer; Microvessel density; Prognosis; Survival; Upper GI bleeding; VEGF

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; STOMACH CANCER; TUMOR CELL; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; ANTIGENS, CD34; BIOPSY; CARCINOMA; ENDOSONOGRAPHY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROVESSELS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROMANIA; STOMACH NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954667439     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
2. Wang YD, Wu P, Mao JD, Huang H, Zhang F. Relationship between vascular invasion and microvessel density and micrometastasis. World J Gastroenterol 2007; 13: 6269-6273.
3. Zhao HC, Qin R, Chen XX, et al. Microvessel density is a prognostic marker of human gastric cancer. World J Gastroenterol 2006; 12: 7598-7603.
4. Affara NI, Robertson FM. Vascular endothelial growth factor as a survival factor in tumor-associated angiogenesis. In Vivo 2004; 18: 525-542.
5. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106: 148-156.
6. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
7. Katano M, Nakamura M, Fujimoto K, Miyazaki K, Morisaki T. Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg 1998; 227: 365-371.
8. Vagenas K, Spyropoulos C, Gavala V, Tsamandas AC. TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. J Surg Res 2007; 15; 139: 182-188.
9. Ding S, Li C, Lin S, et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol 2006; 37: 861-866.
10. Takahashi R, Tanaka S, Kitadai Y, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003; 64: 266-274.
11. Shiyan L, Pintong H, Zongmin W, et al. The relationship between enhanced intensity and microvessel density of gastric carcinoma using double contrast-enhanced ultrasonography. Ultrasound Med Biol 2009; 35: 1086-1091.
12. Gastric cancer. In AJCC Cancer Staging Handbook: TNM Classification of Malignant Tumors. Springer Verlag Berlin 2002; 10: 1111-1118.
13. Kolev Y, Uetake H, Iida S, Ishikawa T, Kawano T, Sugihara K. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 2007; 14: 2738-2747.
14. Kim HS, Kang HS, Messam CA, Min KW, Park CS. Comparative evaluation of angiogenesis in gastric adenocarcinoma by nestin and CD34. Appl Immunohistochem Mol Morphol 2002; 10: 121-127.
15. Lazǎr D, Tǎban S, Raica M, et al. Immunohistochemical evaluation of the tumor neoangiogenesis as a prognostic factor for gastric cancers. Rom J Morphol Embryol 2008; 49: 137-148.
16. Cabuk D, Basaran G, Celikel C, et al. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology 2007; 72: 111-117.
17. Konno H, Baba M, Tanaka T, et al. Overexpression of vascular endothelial growth factor is responsible for the hematogenous recurrence of early-stage gastric carcinoma. Eur Surg Res 2000; 32: 177-181.
18. Tzanakis N, Gazouli M, Rallis G, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 2006; 94: 624-630.
19. Iwasaki J, Nihira S. Anti-angiogenic therapy against gastrointestinal tract cancers. Jpn J Clin Oncol 2009; 39: 543-551.
20. Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 2009; 21: 381-385.
21. Ninomiya S, Inomata M, Tajima M, et al. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice. J Surg Res 2009; 154: 196-202.
22. Lambert K, Ward J. The use of thalidomide in the management of bleeding from a gastric cancer. Palliat Med 2009; 23: 473-475.
23. Tamiya A, Yamazaki K, Boku N, et al. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol 2009; 14: 513-517.
24. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14: 862-870.
25. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-477.